ATRA Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of -38.75% compared to Atara Biotherapeutics's net margin of 12.41%. Atara Biotherapeutics's return on equity of -2818.48% beat Boston Scientific's return on equity of 8.96%.

Atara Biotherapeutics has a consensus price target of $12.25, signalling upside risk potential of 70.85%. On the other hand Boston Scientific has an analysts' consensus of $115.62 which suggests that it could grow by 16.91%. Given that Atara Biotherapeutics has higher upside potential than Boston Scientific, analysts believe Atara Biotherapeutics is more attractive than Boston Scientific.

Atara Biotherapeutics has a beta of 0.487, which suggesting that the stock is 51.322% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.845%.

Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Atara Biotherapeutics quarterly revenues are $32.8M, which are smaller than Boston Scientific quarterly revenues of $4.6B. Atara Biotherapeutics's net income of -$12.7M is lower than Boston Scientific's net income of $566M. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 79.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.42x versus 8.78x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -38.75% compared to Atara Biotherapeutics's net margin of -117.16%. Atara Biotherapeutics's return on equity of -2818.48% beat Moderna's return on equity of -29.09%.

Atara Biotherapeutics has a consensus price target of $12.25, signalling upside risk potential of 70.85%. On the other hand Moderna has an analysts' consensus of $54.14 which suggests that it could grow by 55.97%. Given that Atara Biotherapeutics has higher upside potential than Moderna, analysts believe Atara Biotherapeutics is more attractive than Moderna.

Atara Biotherapeutics has a beta of 0.487, which suggesting that the stock is 51.322% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Atara Biotherapeutics quarterly revenues are $32.8M, which are smaller than Moderna quarterly revenues of $956M. Atara Biotherapeutics's net income of -$12.7M is higher than Moderna's net income of -$1.1B. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.42x versus 4.21x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -38.75% compared to Atara Biotherapeutics's net margin of -49.65%. Atara Biotherapeutics's return on equity of -2818.48% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Atara Biotherapeutics has a consensus price target of $12.25, signalling upside risk potential of 70.85%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.89%. Given that Atara Biotherapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Atara Biotherapeutics is more attractive than NovaBay Pharmaceuticals.

Atara Biotherapeutics has a beta of 0.487, which suggesting that the stock is 51.322% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Atara Biotherapeutics quarterly revenues are $32.8M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Atara Biotherapeutics's net income of -$12.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.42x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

SpringWorks Therapeutics has a net margin of -38.75% compared to Atara Biotherapeutics's net margin of -125.59%. Atara Biotherapeutics's return on equity of -2818.48% beat SpringWorks Therapeutics's return on equity of -46.69%.

Atara Biotherapeutics has a consensus price target of $12.25, signalling upside risk potential of 70.85%. On the other hand SpringWorks Therapeutics has an analysts' consensus of $72.88 which suggests that it could grow by 46.22%. Given that Atara Biotherapeutics has higher upside potential than SpringWorks Therapeutics, analysts believe Atara Biotherapeutics is more attractive than SpringWorks Therapeutics.

Atara Biotherapeutics has a beta of 0.487, which suggesting that the stock is 51.322% less volatile than S&P 500. In comparison SpringWorks Therapeutics has a beta of 0.757, suggesting its less volatile than the S&P 500 by 24.323%.

Atara Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SpringWorks Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Atara Biotherapeutics pays -- of its earnings as a dividend. SpringWorks Therapeutics pays out -- of its earnings as a dividend.

Atara Biotherapeutics quarterly revenues are $32.8M, which are smaller than SpringWorks Therapeutics quarterly revenues of $61.5M. Atara Biotherapeutics's net income of -$12.7M is higher than SpringWorks Therapeutics's net income of -$77.3M. Notably, Atara Biotherapeutics's price-to-earnings ratio is -- while SpringWorks Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Atara Biotherapeutics is 0.42x versus 19.28x for SpringWorks Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.